Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation

NCT00866918 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00866918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00866918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
March 9, 2009
Completion date
September 30, 2022
Enrollment
106 (actual)
Sites
121

Conditions

As the registry lists them; a condition with its own page is linked.

childhood acute promyelocytic leukemia with pml-rara, myeloid neoplasm